Evidence map›Paper›PMID 41817937›Full record

ArticleAnnals of surgical oncology2026

Clinical Significance of Bromodomain-Containing Protein 9 in Colorectal Cancer.

Yoshinao Chinen, Tsuyoshi Hata, Mitsunobu Takeda, Yuki Sekido, Atsushi Hamabe, Takayuki Ogino, Norikatsu Miyoshi, Mamoru Uemura, Hirofumi Yamamoto, Hidetoshi Eguchi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoshinao ChinenDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Tsuyoshi HataDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan. tsuyoshihata@gesurg.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0001-6616-9069
Mitsunobu TakedaDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Yuki SekidoDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Atsushi HamabeDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Takayuki OginoDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Norikatsu MiyoshiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Mamoru UemuraDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Hirofumi YamamotoDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita City, Osaka, Japan.

Funding

JSPS KAKENHI Grant Number 22K07170 to T. Hata.
6 · The paper itself

Abstract

backgroundSwitch/sucrose nonfermentable (SWI/SNF) complexes regulate gene expression through chromatin remodeling and include a recently reported subtype non-canonical BAF (ncBAF). The BRD9 gene that plays a central role in forming ncBAF has been reported to be a poor prognostic factor for various carcinomas. However, the role of BRD9 in colorectal cancer (CRC) has rarely been explored.

methodsIn this study, resected specimens acquired from 124 patients who underwent colorectal resection at our institution between January 2013 and December 2013 were immuno-stained and analyzed.

resultsThe BRD9 high-expression groups exhibited poor prognoses in terms of overall and disease-free survival rates; moreover, high expression was identified as an independent prognostic factor via multivariate analysis. The BRD9 knockdown predominantly decreased the migration and proliferation abilities in the human CRC cell line compared with in the negative controls. RNA sequencing suggested the potential association of BRD9 with 13 genes, including CCN1. In a mouse subcutaneous tumor model, the BRD9 knockdown significantly reduced tumorigenesis compared with that in the negative control.

conclusionsThese results indicate that BRD9 is an independent poor prognostic factor in CRC and is involved in tumor proliferation, migration, and tumorigenicity through the CCN1-mediated enhancement of cancer cell malignancy.

Indexed as

Biomarkers, TumorColorectal NeoplasmsTranscription FactorsAgedAnimalsApoptosisBromodomain Containing ProteinsCell MovementCell ProliferationFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeBiomarkers, TumorBRD9 protein, humanBromodomain Containing ProteinsTranscription FactorsBRD9Bromodomain proteinColorectal cancerE2F pathwayImmunohistochemical stainingSurvival analysis

Identifiers

PMID41817937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.